ADE (chemotherapy)

ADE
ADE
Specialty	oncology

ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy.

ADE regimen consists of three drugs:

Ara-C (cytarabine) - an antimetabolite;
Daunorubicin - an anthracycline antibiotic that is able to intercalate DNA and thus disrupt the cell division cycle, preventing mitosis;
Etoposide - a topoisomerase inhibitor.^[1]

Dosing regimen

Drug	Dose	Mode	Days
Ara-C (cytarabine)	200 mg/m²	IV push every 12 hours in 2 divided doses (100 mg/m² each)	Days 1-10
Daunorubicin	50 mg/m²	IV slow push	Days 1, 3 and 5
Etoposide	100 mg/m²	IV infusion over 1 hour	Days 1-5

References

↑ Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

[1]